A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations

Axel Bex, Laurence Albiges, Michael Staehler, Karim Bensalah, Rachel H. Giles, Saeed Dabestani, Fabian Hofmann, Milan Hora, Markus A. Kuczyk, Thomas B. Lam, Lorenzo Marconi, Axel S. Merseburger, Sergio Fernández-Pello, Rana Tahbaz, Yasmin Abu-Ghanem, Alessandro Volpe, Börje Ljungberg, Bernard Escudier, Thomas Powles

Forskningsoutput: TidskriftsbidragLetterPeer review

3 Citeringar (SciVal)
Originalspråkengelska
Sidor (från-till)849-851
Antal sidor3
TidskriftEuropean Urology
Volym74
Utgåva6
DOI
StatusPublished - 2018

Ämnesklassifikation (UKÄ)

  • Cancer och onkologi
  • Urologi och njurmedicin

Citera det här